ERBB2 and breast carcinoma: Although trastuzumab as single agent has been proved active and well tolerated in treatment of breast cancer with ErbB2 overexpression [17], many tumors overexpressing ErbB2 do not respond to trastuzumab monotherapy, and acquired resistance does often develop [18,19].